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Abstract
Colorectal cancer (CRC) is the third most commonmalignancy and the second leading cause of cancer-related deaths
in America. Nearly two thirds of newly diagnosed CRC cases include lymph node (LN) involvement, and LNmetastasis
is one of the strongest negative prognostic factors for CRC. It is thought that CRC tumors contain a small population of
drug-resistant CRC tumor-initiating cells (Co-TICs) that may be responsible for cancer recurrence. To evaluate the
effects of the LN stromal cells on Co-TICs, we established a unique xenoplant model using CRC cells isolated by
enzymatic digestion from consented patient specimens, HT-29 cells, HCA-7 cells, and LN stromal cell line HK cells.
We found that HK cells and HK cell–conditioned media enhanced CRC tumor formation and tumor angiogenesis. Cells
expressing CD133+ and the stromal cell–derived factor 1α (SDF-1α) receptor CXCR4were enriched in chemotherapeutic-
resistant CRC cells. CD133+CXCR4+ Co-TICs isolated from patient specimens are more tumorigenic than unsorted
tumor cells. Furthermore, the inhibitors specific to HK cell–derived SDF-1α reduced tumor formation and tumor
angiogenesis. Our results have demonstrated a role for Co-TICs in tumor growth and defined the influence of LN
stromal cells on Co-TICs. We have identified a major Co-TIC/LN microenvironment-specific mechanism for CRC resis-
tance to chemotherapeutic agents and established experimental platforms for both in vitro and in vivo testing, indi-
cating that SDF-1α and its receptor, CXCR4, may be targets for clinical therapy.
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Introduction
In the United States, colorectal cancer (CRC) is the third most com-
mon malignancy and the second most common cause of cancer-related
mortality, with an estimated incidence of 143,000 cases and 51,000
deaths per year [1]. Despite the standard treatment of surgery and che-
motherapy in advanced CRC, there is approximately 50% recurrence.
Tumor-initiating cells (TICs) that are resistant to conventional chemo-
therapeutic and radiation treatments may be responsible for this tumor
recurrence [2].
Current CRC therapies fail to effectively prevent extranodal CRC
recurrence, even in cases of successful eradication of all visible tumors.
These therapies inadequately treat the rare but highly significant popula-
tion of CRC tumor-initiating cells (Co-TICs) [3] and ignore the tumor-
nurturing role that the lymph node (LN) microenvironment plays.
LN metastasis is one of the strongest negative prognostic factors
for CRC. Most CRC patients present with regional LN involvement,
stage III disease, suggesting that the LN microenvironment plays a
significant role promoting extranodal recurrence and further metas-
tasis [4]. Follicular dendritic cells (FDCs), unique LN stromal cells
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that display both autocrine and paracrine properties, analogous to
cancer-associated stromal fibroblasts, have been shown to nurture
CRC cells through production of various cytokines and growth fac-
tors [5]. CRC cells interact with tumor-fostering stromal cells and the
extracellular matrix in a protective fashion decreasing chemotherapy-
induced apoptosis [6].
Various chemokines play important roles in TICs/stromal cell
niche interaction. The stromal cell–derived factor 1α (SDF-1α) is a
chemokine that regulates many essential biologic processes including
revascularization, cellular adhesion, and tumorigenesis [7]. It has a
negative effect in multiple cancers [8]. Previous studies have shown
that SDF-1α and its membrane-bound receptor chemokine receptor
4 (CXCR4) are involved in tumor metastasis and extranodal recurrence
in CRC [9–11] and that the metastatic activity of CD133+CXCR4+
TICs is increased in pancreatic cancer [12].
The accumulated evidence indicates that TICs are supported by
microenvironmental factors produced by surrounding stromal cells.
However, little is known about the role that LN stromal cells play
in providing a supportive microenvironment to allow for Co-TICs
survival, activation, and stimulation. Furthermore, it is unclear how
this supportive LN microenvironment results in extranodal tumor re-
currence despite appropriate oncologic treatment. We hypothesized
that the LN stromal microenvironment, specifically FDC, primes
Co-TICs activation through the SDF-1α/CXCR4 axis and plays a
key role in supporting therapy-resistant Co-TICs that have metasta-
sized to the LN. This microenvironment also facilitates cellular edu-
cation, supporting and promoting extranodal metastasis. In this
study, we evaluated the effect of LN stromal cells, specifically the
effect of the SDF-1α/CXCR4 axis, on Co-TICs, using CRC patient
specimens, HT-29, and HCA-7 cell lines in a unique CRC xenoplant
model. By understanding the LN’s stromal effect on Co-TICs, we
hope to better predict tumor recurrence and develop targeted therapy
for minimizing extranodal CRC recurrence.
Materials and Methods
Antibodies and Reagents
Antibodies (Abs) used were phycoerythrin (PE)-labeled mouse
antihuman CD133 (clone 923C3; Miltenyi Biotec, Auburn, CA),
CXCR4 (clone 12G5; R&D Systems, Inc, Minneapolis, MN), CD326
(EpCAM; Miltenyi Biotec), antimouse CD31 (PECAM-1, clone
MEC13.3; BD Biosciences, San Jose, CA), and mouse isotype control
IgG (clone MOPC-21; BD Biosciences); Allophycocyanin (APC)-
conjugated CD133 (clone AC133; Miltenyi Biotec) and mouse isotype
controls (clone MOPC-21 Inc. BD Biosciences); biotinylated goat
antirabbit or antimouse IgG (R&D Systems); horseradish peroxidase–
conjugated streptavidin ( Jackson Laboratory, Bar Harbor, ME); fluo-
rescein isothiocyanate–conjugated goat antimouse IgG (BD Bio-
sciences); rabbit anti–human CD133 (Abcam, Inc, Cambridge, MA);
anti–cytokeratin 20 (Abcam, Inc); and anti–mucin 1 (Santa Cruz Bio-
technology, Santa Cruz, CA). Reagents used were Sigma FAST 3,3-
diaminobenzidine tablets (Sigma-Aldrich, St Louis, MO) and human
SDF-1α–specific ELISA Kit (R&D Systems). The chemotherapeutic
drugs used were 5-fluorouracil (5-FU; APP Pharmaceuticals LLC,
Schaumburg, IL) and oxaliplatin (Hospira, Inc, Lake Forest, IL).
Cell Lines
An FDC cell line, HK, was maintained in RPMI medium supple-
mented with 10% fetal calf serum (FCS, Life Technologies, Grand
Island, NY), 2 mM glutamine, 100 U/ml penicillin G, and 100 mg/ml
streptomycin (Irvine Scientific, Santa Ana, CA) [13]. Colon cancer cell
lines HT-29 and HCA-7 were purchased from the American Type
Culture Collection (ATCC, Manassas, VA). CRC-Pt1 is a colon cancer
cell line derived from primary tumor in nonobese diabetic/severe com-
bined immunodeficient (NOD/SCID) mice generated by coinjection
of cancer cells isolated from colon cancer patient 1 andHK cells. All cell
cultures were carried out in McCoy medium with supplements at 37°C
in a 5% CO2 humidified incubator.
Isolation of Single-Cell Suspension from
Colon Cancer Specimens
Human CRC tissue specimens were obtained in accordance with the
ethical standards of the institutional committee on human experimen-
tation from consented patients undergoing a colon or rectal resection
for colorectal adenocarcinoma. Histologic diagnoses were based on
microscopic features of carcinoma cells determining the histologic type
and grade. Colon cancer and normal colon tissues were collected in cold
sterile McCoy medium containing penicillin G (500 U/ml) and strep-
tomycin (500 mg/ml). Tissues were mechanically minced into small
pieces. Enzymatic digestion was performed using collagenase IV
(1.5 mg/ml), hyaluronidase (20 mg/ml), and deoxyribonuclease I
(DNase I, 0.1 mg/ml; all from Sigma-Aldrich) in Hank’s balanced salt
solution for 2 to 3 hours at 37°C. The digests were used for pheno-
typing with Co-TIC markers, direct engraftment in immunodeficient
mice, and purification of Co-TICs.
FACS Analysis
For cell surface Ag staining, enzyme-digested suspension colon
cancer cells, control colon cells, or adhesion colon cancer cells de-
tached by trypsin from monolayer cultures were incubated with the
indicated Abs directly conjugated with PE or APC in the manufac-
turer’s suggested concentration for 15 minutes at 4°C. Isotype-control
Abs were used at the same concentration for background-level stain-
ing. After washing with phosphate-buffered saline containing 0.2%
bovine serum albumin and 0.1% sodium azide, cells were acquired
by a FACSCalibur using CellQuest software (BD Biosciences) and
were analyzed using FlowJo software (Tree Star, Inc, Ashland, OR).
Viable cells were gated by forward and side scatters.
Immunohistochemistry Using Frozen and
Paraffin-Embedded Slides
For histologic evaluation, one portion of each colon cancer patient
specimen and xenoplant tumor tissue were fixed in formalin and
embedded in paraffin. Another portion was embedded in OCT com-
pound (Tissue Tek, Sakura Finetek USA, Torrance, CO) and stored
at −80°C. Tissue slides were subjected to hematoxylin and eosin stain-
ing as well as immunohistochemistry staining. For immunofluorescent
staining on cryosections, PE-conjugated antimouse CD31 (1:50) was
used to quantify angiogenesis in xenoplants. APC- or PE-conjugated
antihuman CD133 (1:50) and PE- or peridinin chlorophyll protein
(PerCP)-conjugated antihuman CXCR4 (1:50) Abs were used to iden-
tify Co-TICs. FITC-conjugated CD326 (1:50) was used as marker for
colon cancer cells. The 4′,6-diamidino-2-phenylinodole (DAPI) was
used for nuclei counterstaining (ProLong Gold antifade reagent with
DAPI; Invitrogen, Eugene, OR).
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Paraffin-embedded tissue sections (5 μm) were deparaffinized, re-
hydrated, and blocked for endogenous peroxidase activity. After
high-temperature Ag retrieval in Trilogy unmasking solution (Cell
Marque, Rocklin, CA), slides were biotin-blocked, serum-blocked,
and immunostained using EnVision G/2 double-stain system, rabbit/
mouse kit (DAB+/Permanent Red; Dako, Glostrup, Denmark) accord-
ing to the manufacturer’s instructions. Abs to CD133 and CXCR4
were applied at 1:50 for 1 hour at room temperature. Slides were
counterstained with hematoxylin. All images were captured by a
deconvoluting microscope using the SlideBook software (all from
Intelligent Imaging Innovations, Inc, Denver, CO).
Isolation of Co-TICs Using Magnetic Cell Sorting and
Flow Cytometry
The epithelial cell adhesion molecule (EpCAM or CD326) expres-
sion was used to ensure that the CD133+ cells corresponded to cancer
cells of human epithelial origin. Magnetic cell separation was per-
formed on cells obtained from enzymatic dissociation of colon cancer
specimens and HT-29 cells using anti–CD326-APC followed by
microbeads conjugated to anti-APC and then microbeads conjugated
anti-CD133 (AC133) Ab after cleavage of the beads. The magnetic
separation step was repeated twice, applying the eluted positive cells to
a new magnetic column for positive selection. After magnetic sorting,
cell viability was assessed using trypan blue exclusion. Quality of
sorting was examined by flow cytometry with an Ab against
CD133 (293C3-PE) on CD133+ cell population. To purify
CD133+CXCR4+ cells from the patient’s specimen, CD326-FITC–,
CXCR4-PE–, and CD133-APC–positive cells were identified and
electronically gated for cell sorting on a FACS Aria cell sorter using
Becton Dickinson Diva software (BD Biosciences).
Preparation of GFP-Tagged CRCs
HT-29 or CRC-Pt1 cells were cultured in 500 μl of McCoymedium
with 10% FCS without antibiotics in 12-well plates (5 × 105 cells/well).
GFP-expressing lentivirus pLentiLox3.7 (200 μl), medium (300 μl),
and 6 μg/ml polybrene were added to each well. After 12 hours of
incubation, 2 ml of fresh medium was added. After expansion, GFP+
cells were enriched by FACS cell sorting twice.
In Vitro Colon Cancer Cell Proliferation Assay
GFP-tagged colon cancer cells (2 × 104 cells/well) were cultured in
McCoy medium containing 10% fetal calf serum with HK cells (2 ×
104 cells/well) that were seeded 1 day prior in 24-well plates. In some
experiments, HK cell–conditioned McCoy medium was added to the
cancer cells or HK cells were separated from the cancer cells by a
transwell chamber with 0.4-μm pore filters (Corning Life Sciences,
Lowell, MA). The chemotherapeutic drug 5-FU or oxaliplatin was
added to the cell culture on day 2. GFP signals of viable cancer cells were
measured by IVIS Lumina Imaging System; images were analyzed using
Living Image Software (both from Caliper Life Sciences, Hopkinton,
MA), and data were presented as efficiency × 10−3.
In some experiments, the cell proliferation reagent WST-1 was
used according to the manufacturer’s instructions to determine cell
proliferation and viability (Roche Applied Science, Indianapolis, IN).
Cells grown in a 96-well tissue culture plate were incubated with the
ready-to-use WST-1 reagent for 1 hour to 3 hours. The formazan
dye formed by metabolically active cells in the culture was quantified
with an ELISA reader at OD650-450nm (Bio-Rad, Hercules, CA).
Colon Cancer Cell Sphere Formation by Extreme Limiting
Dilution Analysis
Extreme limiting dilution analysis was performed as described by
Hu and Smyth [14]. Briefly, serum-free stem cell medium (SCM)
contains Dulbecco modified Eagle medium/F12 (GIBCO, Invitrogen
Corporation, Carlsbad, CA) supplemented with 10 ng/ml basic fibro-
blast growth factor, 20 ng/ml epidermal growth factor, 1 × B27 supple-
ment (Sigma), 2mM glutamine, 100U/ml penicillin G, and 100mg/ml
streptomycin. HK cell–conditioned medium was collected by cul-
turing 0.5 million cells in 10 ml of SCM for 72 hours. HT-29 and
HCA-7 single-cell suspension obtained from adherent cell cultures by
trypsin were plated at concentrations of 10,000, 1000, 100, and 10 cells
and 1 cell per well per 200 μl of SCM or 50% serum-free HK cell–
conditioned medium in ultra–low-attachment 96-well plates and were
incubated for 10 days (12-24 wells for each dilution). At the end of
10 days, the number of wells showing formation of colonospheres
was counted using Leica Microscope (Leica Microsystems, Wetzlar,
Germany). The frequency of sphere-forming cells in a particular cell
type was determined using the extreme limiting dilution analysis Web
tool at http://bioinf.wehi.edu.au/software/elda.
Tumorigenicity
Male nude and NOD/SCID mice, 6 to 8 weeks old, were obtained
from the National Cancer Institute, Frederick Cancer Research Fa-
cility (Frederick, MD) and were acclimated for 1 week. All animal
studies were conducted under approved guidelines of the Animal Care
and Use Committee of the Ochsner Clinic Foundation. Varying
doses of HT-29, HCA-7, CRC-Pt1, or purified CD133+ CRC cells
were mixed with HK cells (1 × 106) in 0.1 ml of McCoy medium and
then injected subcutaneously with a 25-gauge needle into the poste-
rior flank of the mice. In some experiments, CRC cells were pre-
incubated with 50 μM AMD3100 (Sigma) for 30 minutes at 37°C.
Tumorigenesis was assessed by measuring solid tumors in three di-
mensions with calipers twice a week. Tumors were removed when
they became 1 cm3.
Statistical Analysis
Data presented are representatives of at least three similar indepen-
dent experiments. To assess statistical significance of differences, an
unpaired t test (Prism Version 4.03; GraphPad Software, Inc, La Jolla,
CA) was used. P < .05 was considered significant (*), and P < .001 was
considered very significant (***). Linear regression method was used
to analyze the correlation between GFP signal and WST-1 assay for
viable cell quantification. The R2 value was used to assess significance.
Results
FDC/HK Cells Promote Colon Cancer Cell Tumor Formation
in Immunodeficient Mice
LN involvement positively correlates to poor prognosis of CRC.
It was reported that the addition of stromal cells to a small number
of HT-29 cells, which, in themselves, are unable to induce tumors,
allowed the development and growth of tumors in nude mice [15]. To
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evaluate the role of LN stromal cells in tumor growth and to quanti-
tatively evaluate the presence of TICs, we established an in vivo CRC
tumor model using HT-29 cells and FDC cell line HK cells. In this
model, varying doses of HT-29 cells were coinoculated subcutaneously
with or without HK cells into nude mice for tumor formation. As
shown in Figure 1A and Table 1, the addition of HK cells increased
tumor formation especially in lower doses of HT-29 cell.
To examine whether CRC cells from patients are tumorigenic
in this model, enzyme-digested single-cell suspensions of human
cancer cells were inoculated into NOD/SCID mice. As indicated
in Table 1 and Figure 1B, 13 of 36 injections of suspension cancer
cells (0.01-1 × 106 cells/site) formed tumors in the presence of HK
cells, while only 2 tumors were formed in 36 cancer cell injections
without HK cells. Injection of HK cells alone did not form tumors.
The xenograft resembles the original tumors in morphology as well
as cytokeratin 20 and Mucin 1 expression (Figure 1C ). These data
suggest that HK cells play a key role in cancer cell survival, tumor
initiation, and growth in vivo and that HT-29 cells and patients’
specimens contain TICs.
Soluble Factors Produced by FDC/HK Promote Colon Cancer
Cell Proliferation, Sphere Formation, and Tumor Formation
To evaluate the FDCs’/HK cells’ effects on CRC cells, we then
established an in vitro CRC proliferation assay. First, we confirmed
that the GFP signal from viable cells correlated with the WST-1 assay
Figure 1. FDC/HK cells support HT-29 cell and CRC patient cancer cell tumor formation in immunodeficient mice. (A) HT-29 cell tumor
formation in nude mice. HT-29 cells (2 × 105) were subcutaneously injected with or without HK cells (1 × 106) into the posterior flank of
nude mice. Graph shows tumor size measured with a caliper in three dimensions at the indicated days after cell injection. (B) Single-
suspension cancer cells from patient 1 (2 × 105) were subcutaneously injected with or without HK cells (1 × 106) into the left posterior
flank of NOD/SCID mice (arrows). Images show patient’s colon cancer cells form tumor in the presence of HK cells (top), whereas no
tumor was formed without HK cells (middle) or with HK cells alone (bottom). (C) Hematoxylin and eosin staining of paraffin-embedded
original tumor and tumor from xenograft showing similarity in cancer morphology, and cytokeratin 20 (CK20) and Mucin 1 staining
positive in the xenograft tumor. Images were captured by a deconvoluting microscope using SlideBook software. Original magnifi-
cation, ×400.
Table 1. CRC Cells Are Tumorigenic in Immunodeficient Mice.
Cancer Cells Injected Tumor Formation/Injection
1 × 106 1 × 105 1 × 104 1 × 103 1 × 102
HT-29 4/4 3/5 0/4 0/2
HT-29 + HK 4/4 6/6 5/6 1/3
HT-29 CD133+ 0/6 0/2 0/2
HT-29 CD133+ + HK 4/6 5/6 1/3
Pt cancer 2/20 0/14 0/2
Pt cancer + HK 6/20 6/14 1/2
Pt cancer CD133+ 0/2 0/6
Pt cancer CD133 ++ HK 2/2 1/6
Pt cancer CD133+CXCR4+ + HK 2/2
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(Figure W1). To monitor cancer cell proliferation in CRC cell and
stromal cell cocultures, HT-29 cells and tumor cells isolated from
patient 1 (CRC-Pt1) were tagged with GFP and then cultured with
and without HK cells. Results show that HK cells promoted CRC
cell proliferation in a dose-dependent manner as measured by IVIS
Lumina Imaging System by quantifying the GFP signals (Figure 2A).
When HK cells were separated from HT-29 cells by transwells
(Figure 2B) or when HK cell–conditioned medium was added to the
HT-29 or HCA-7 cell cultures (Figures 2C and 4, B and C ), a signifi-
cant supporting effect was observed, indicating that soluble factors
secreted from stromal cell HK, rather than cell-cell contact, are involved.
The ability of CRC cells to form spheres in serum-free culture con-
ditions is not only an indication of cell self-renewal but also a charac-
teristic of Co-TICs [16,17]. When HT-29 and HCA-7 cells were
tested, the addition of HK cell–conditioned media increased HT-29
and HCA-7 cell sphere formation significantly (Figure 2D and
Table W1). One of 308 HT-29 cells and 1 of 200 HCA-7 cells formed
spheres in 10 days when cells were seeded in serum-free SCM. When a
50% serum-free HK cell–conditioned medium was added to the cul-
tures, 1 of 29 HT-29 cells and 1 of 8 HCA-7 cells formed spheres. This
is consistent with the idea that TICs are only a small population of can-
cer cells. Supporting effects of HK cell–conditioned medium are also
confirmed by in vivo tumor formation assay. In NOD/SCID mice,
the addition of HK cells significantly enhanced HT-29 and HCA-7 cell
tumor formation, whereas the presence of HK cell–conditioned media
partially supported HT-29 and HCA-7 cell tumor formation (Figure 2,
E and F ). These data suggest that soluble factors produced by HK
cells are sufficient to support sphere-forming Co-TICs in HT-29 and
HCA-7 cells.
Identification of Co-TICs in CRC Cells
It has been documented that Co-TICs express a variety of surface
markers; the most promising marker seems to be CD133 [18]. Al-
though CD133 expression is a prognostic marker for colon cancer, it
may lack a functional role in tumor with initiation [19], and CD133+
CRC cells represent a heterogeneous population of cells. Because solu-
ble factors are involved in supporting Co-TICs, chemokine SDF-1α is
one of the soluble factors known to be produced by FDCs in LNs, and
TICs express an additional marker CXCR4, themembrane-bound recep-
tor for SDF-1α, that has increased metastatic activity in pancreatic
cancer [12], we examined CXCR4 as a Co-TIC marker in addition
to CD133. When the two markers CD133 and CXCR4 were used
in CRC specimens, a distinct population of cancer cells was detected
in paraffin-embedded tissue as well as in fresh frozen tumor specimens,
indicating that CRC tumors contain a small fraction of CD133+
CXCR4+Co-TIC (Figures 3,A andB, andW2A).To identify andquantify
the presence of Co-TIC, colon cancer cell lines HT-29 and HCA-7 and
enzyme-digested single-cell suspension tumor cells from 21 CRC patients
were examined using FACS analysis with Abs specific to CD133
Figure 2. FDC/HK cells support CRC cell proliferation, sphere formation, and tumor formation. (A-C) CRC cell proliferation. GFP-tagged
HT-29 (3000 cells/well) and CRC-Pt1 (1000 cells/well) cells were cocultured with indicated numbers of HK cells in 96 well plates for
72 hours (A). GFP-tagged HT-29 cells were cultured alone, with HK cells, or with HK cells separated by a transwell in 24-well plates
for 48 hours (B). GFP signals were evaluated by IVIS Lumina Imaging System (A and B), and WST-1 assay for HCA-7 cells was measured
by OD650-450 nm after 72 hours of incubation with or without 50% HK cell–conditioned medium (C). (D) A log-fraction plot of the limiting
dilution model fitted to the data in Table W1. The slope of the line is the sphere formation cell fraction for HT-29 and HCA-7 cells. The
dotted lines give the 95% confidence interval. Black line for SCM and red lines for 50% HK cell-conditioned medium. (E and F) HK cells
and HK cell–conditioned medium support HT-29 and HCA-7 cell tumor formation in NOD/SCID mice. CRC tumor formation was indicated
by GFP signal imaging (for GFP-HT-29 cells), and tumor size was measured by a caliper (for HCA-7 cells) in the absence or the presence
of HK cell or HK cell–conditioned media.
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Figure 2. (continued).
Neoplasia Vol. 13, No. 9, 2011 Co-TIC and LN Microenvironment Margolin et al. 879
and CXCR4. Figure 3C shows that HT-29, HCA-7 cells, and patient
tumors cells all contain small populations of CD133+CXCR4+ cells.
Although consistently present (17/18 patients tested), the percentage
of Co-TIC in patient specimens varies (from 0.05 to 7.39; Table 2).
This double-positive population is not seen in normal control colon
cell suspensions (Figure 3C ). CXCR4 is known to be expressed on
a variety of cell subtypes. In Figure W2A, a triple-Ab staining
shows that the CD133 and CXCR4 double-positive cells are also
CD326-positive.
CD133+ CRC Cells Are More Tumorigenic than
Unseparated Cells
CD133 has been documented as a TIC marker in HT-29 cells [20].
To enrich CD133 highly expressed CRC cells, HT-29 and CRC
Figure 3. Detecting Co-TICs in CRC. (A) Paraffin-embedded tumor tissue sections from CRC patients 1 and 4 were double stained for
CD133 (brown) and CXCR4 (pink) and control Ab staining. Arrows show double-positive cells. Hematoxylin was used as a counterstain.
Original magnification, ×400. (B) Frozen tumor tissue sections from CRC patients 5 and 8 were double stained for CD133 (red) and
CXCR4 (green, arrows). DAPI was used as a nuclear counterstain. Original magnification, ×400. (C) Double staining of CD133 and
CXCR4 on patient’s normal colon cells or CRC patient cells (left panels) and HT-29 cells or HCA-7 cells (right panels). Numbers indicate
percentage of cells in quadrants. Isotype control mouse IgGs (mIgG) were used for background-level staining.
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patient’s cells were magnetically labeled with anti-CD133 and separated
by MACS column. As indicated by flow cytometry analysis for CD133
staining, magnetic cell sorting significantly enriched CD133high HT-29
cells (purity was enriched from 57% to 82% and mean fluorescence
intensity for CD133 increased from 29 to 252) and CRC-Pt7 cells
(from 7% to 71% and mean fluorescence intensity increased from 6
to 46; Figure W3).
In a limiting dilution assay [18], using different doses of unsorted
HT-29 cells or MACS column–purified CD133high HT-29 cells (1 ×
102 to 1 × 106) for tumor formation in nude mice with or without
HK cells (1 × 106), we found, in the presence of HK cells, that
CD133high HT-29 cells formed tumors with lower doses of cells
compared with unsorted cells (Table 1). In fact, we were able to form
tumors in 10 of 15 nude mice with as little as 100 CD133high HT-
29 cells in the presence of HK cells (Table 1). At these low doses of
HT-29 cells, no tumor was formed without HK cells. These data
further demonstrate the CD133high cell population–enriched Co-
TIC and the importance of HK cells in supporting tumor formation.
When MACS column–purified CD133+ cancer cells and FACS
sorting–enriched CD133+CXCR4+ cancer cells from CRC patients
were used for tumor formation in NOD/SCID mice, in the presence
of HK cells, 10,000 CD133+ cancer cells and 100 CD133+CXCR4+
cancer cells formed tumors. There was no tumor formation in the
absence of HK cells (Figure 1B and Table 1). These data suggest
that CD133+CXCR4+ CRC contain enriched Co-TICs.
FDC/HK Cells Protect Chemoresistant Co-TICs In Vitro
and In Vivo
5-FU and oxaliplatin are standard chemotherapeutic agents used
in the treatment of LN-positive CRC, but the development of che-
moresistance and extranodal recurrences does occur [21]. Because
Co-TICs are thought to be resistant to chemotherapy, we hypothe-
sized that Co-TICs can be enriched by exposing CRC cells to che-
motherapy and that HK cells will protect these chemoresistant cancer
cells. Indeed, GFP-tagged HT-29 and CRC-Pt1 cell growth was in-
hibited by 5-FU or oxaliplatin treatment, and HK cells prevented
this inhibition (Figure 4). After 72 hours of incubation in the pres-
ence of HK cells, CRC cell growth inhibition by suboptimal doses of
chemotherapeutic agents was significantly reduced in both HT-29
cells and CRC-Pt1 cells (Figures 4A and W4). When HK cell–
conditioned medium was used to substitute HK cells in the HT-29
cell culture, the inhibitory effects of the chemotherapeutic drugs
were partially blocked (Figure 4, B and C ). The surviving HT-29 cells
from chemotherapy were enriched with CD133highCXCR4+ double-
positive cell populations compared with media-treated control cells
(Figure 4D).
This phenomenon was confirmed with in vivo tumor formation
experiments. HT-29 cells were coinjected with HK cells in nude
mice for tumor formation. Three weeks after the injection, tumor-
bearing mice were randomly assigned to three groups: one was in-
jected with phosphate-buffered saline (intravenously) as medium
control, the second was injected with 5-FU (50 mg/kg, intravenously,
three times per week), and the third group was injected with oxaliplatin
(10 mg/kg, intraperitoneally, once a week). Tumor cells were collected
for Co-TIC marker analysis by FACS 2 weeks after the treatments.
Figure 4D shows CD133highCXCR4+ Co-TICs were enriched in re-
sidual tumor cells after chemotherapy treatments, suggesting that the
presence of FDCs/HK cells promotes drug-resistant Co-TICs’ survival
and proliferation.
FDCs/HK Cells Support Co-TICs by Providing SDF-1α and
Enhancing Tumor Angiogenesis
There are two receptors for SDF-1: CXCR4 and CXCR7 [22].
Studies have shown that SDF-1 and CXCR4 are involved in the meta-
static process of CRC [22]. We first investigated the SDF-1α expression
pattern in CRC LN metastasis. When a CRC specimen and its LN
metastatic tumor from the same patient were stained with SDF-1α
and CXCR4 (Figure 5A), spindle-like stromal cells in the LN but
Table 2. Selected CRC (Adenocarcinoma) Patient Biopsy Characteristics.
Specimens Age (year) Sex Stage Differentiation Tumor Location Markers
Positive (%) in Cancer Cells
CD133 CXCR4 CD133/CXCR4
Pt1 61 F III M Left 0.56 ND ND
Pt2 44 M II M Sigmoid 0.21 ND ND
Pt3 66 F II M Transverse 0.48 ND ND
Pt5 85 M II P Cecum 1.71 5.11 1.72
Pt6 55 M II M Transverse 3.62 5.6 1.02
Pt7 63 M II M Right 4.59 20.32 4.84
Pt8 71 F III P Hepatic flexure 2.24 18.44 1.64
Pt12 67 M II M Sigmoid 0.92 0.94 0
Pt16 75 M III M Rectum 0.73 0.48 0.27
Pt20 39 F III M Cecum 0.98 1.28 0.08
Pt24 77 M III M Rectosigmoid 0.78 1.47 0.7
Pt25 80 F II P Right 0.19 4.66 0.16
Pt26 55 M III P Rectosigmoid 0.33 3.41 0.25
Pt27 44 F III M Right 30.09 12.49 7.39
Pt28 79 M III M Rectosigmoid 1.3 4.62 0.38
Pt30 65 M II M Transverse 0.2 2.6 0.05
Pt32 86 F I P Right 0.5 40.5 0.5
Pt34 47 F II M Sigmoid 27.8 4.2 1.67
Pt35 60 M II M Rectum 0.86 3.22 0.34
Pt36 51 F II M Sigmoid 43.32 14.42 6.22
Pt38 80 F III W Right 0.89 3.26 0.25
Differentiation: M indicates moderately; ND, not tested; P, poor; W, well.
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not CRC cells showed SDF-1α expression. CD133 and CXCR4 ex-
pressions were also increased in CRC metastatic LN compared with
original tumor. Thus, it is possible that soluble SDF-1α produced by
LN stromal cells supports CD133+CXCR4+ Co-TIC, which metasta-
sized to the LN.
To investigate the role of SDF-1α in our CRC tumor model, we
examined the expression of SDF-1α in HK cells. Figure 5B (insert)
shows accumulative SDF-1α production in the culture supernatant
after 72 hours of incubating with titrated doses of HK cells. Minimal
expression of SDF-1α was detected in either HT-29 or CRC-Pt1 cell
cultures. The protein level of SDF-1α was depleted when HK cells
and CRC cells were cocultured, indicating CRC cells’ consumption
of this chemokine (Figure 5B). To determine the role of SDF-1α
produced by HK cells in tumor formation, we used AMD3100, a
CXCR4-specific small-molecule inhibitor that blocks SDF-1α/
CXCR4 interaction. Pretreatment of CRC cells with AMD3100 par-
tially inhibits the HK cell–assisted tumor formation in both HT-29
and CRC-Pt1 cells (Figure 5, C and D).
SDF-1 is also known to support tumor angiogenesis [23]. Tumor
vasculature was detected in tumors formed by HT-29 cells and HK
cells. An Ab against the mouse endothelial cell marker CD31 was
used to reveal host angiogenesis. Comparing CD31-positive staining
between tumors formed by HT-29 cells alone and by HT-29 plus
HK cells, the presence of HK cells significantly enhanced host vascu-
lature development (CD31-positive; Figure 5, E and F , red staining).
This effect was inhibited by AMD3100 treatment of CRC cells before
cell injection, further supporting our hypothesis that stromal HK cells
may assist CRC cells’ tumor formation through SDF-1α and CXCR4
paracrine signaling.
Discussion
The current study indicates that stromal FDCs enhance Co-TIC tumor
formation in the LN microenvironment (Figure 5G ). We have estab-
lished in vitro and in vivo experimental methods using CRC patient
specimens, HT-29, and HCA-7 cells with FDC (in the form of the
human FDC cell line HK) [24]. HK cells express smooth muscle an-
tigen, von Willebrand factor, and vimentin, but not CD31, indicating
that it is a stromal cell (Figure W5, A and B). Although derived from
tonsilar cells, the HK cell line functionally resembles primary FDCs in
supporting germinal center B cells and lymphomas [25,26]. Using co-
culture and coimplantation tumor xenograft models, we demonstrated
that FDCs/HK cells significantly promote the survival and growth of
CRC cells, preferentially CD133+CXCR4+ Co-TICs. FDCs play a cen-
tral role in promoting tumor growth and tumor angiogenesis by recruit-
ing CD31+ endothelial progenitor cells. These effects are mediated in
part by a soluble factor SDF-1α because the CXCR4 antagonist
AMD3100 partially inhibited FDC-enhanced tumor formation in
immunodeficient mice. This function of stromal FDC is similar to that
of carcinoma-associated fibroblasts as seen in breast cancer [27]. These
in vitro and in vivo models are valuable in further elucidating the
effects of LN stromal microenvironment on Co-TICs.
Figure 4. FDC/HK cells support chemoresistant colon cancer cells in vitro and in vivo. (A) Suboptimal doses of 5-FU (400 μM) and ox-
aliplatin (60 μM) were added to the coculture of GFP-tagged CRC cells with HK cells in 96-well plates for 72 hours. Percentage inhibition of
cell growth by GFP signal levels was calculated against that of untreated cells. (B-C) GFP-tagged HT-29 cells were cultured with or without
50%HK cell–conditionedmedia and then treated with 5-FU and oxaliplatin for 72 hours. GFP signals (B) and percentage inhibition of viable
cells by GFP signal levels (C) are shown. (D) CD133+CXCR4+ cells are enriched in chemoresistant HT-29 cells. HT-29 cells after 72 hours
of chemotherapy in A were collected. Tumor-bearing mice were treated with control and chemotherapeutic drugs for 2 weeks as de-
scribed in Results. Enzyme-digested single-cell suspension tumor cells were collected. Both cells were stained with CD133 and CXCR4
and analysis by FACS similar to Figure 3C . Data are presented as mean ± SD. Data show percentage of double-positive cells.
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Figure 5. FDC/HK cells support Co-TIC by providing SDF-1α and enhance host angiogenesis. (A) Immunohistochemistry staining of colon
cancer original tumor, LN metastasis paraffin slides for SDF-1α, CXCR4, and CD133 expression. Arrows show Ab staining–positive cells.
(B) SDF-1α protein levels in 72 hours of culture supernatants of HK cells and/or colon cancer cells were measured by specific ELISA (R&D
Systems). Insert shows SDF-1α levels in HK cell dose titration. (C and D) HK cells promote HT-29 (C) and CRC-Pt1 (D) cells to form
tumors in nude and NOD/SCID mice, respectively. HT-29 or CRC-Pt1 cells (1 × 105) with or without HK cells (1 × 106) were subcuta-
neously injected into the posterior flank of immunodeficient mice. In some experiments, cancer cells were pretreated with AMD3100.
Tumor sizes (mm3) were measured at the indicated time points. (E) Immunohistochemistry staining of frozen slides from tumors formed
by HT-29 cells with or without HK cells using antimouse CD31 Abs (red). DAPI is used for nuclear staining (blue). Images were captured
by a deconvoluting microscope using SlideBook software. Original magnification, ×400. (F) Quantitative analysis of CD31-positive stain-
ing (% area) in tumors formed with HT-29 cells. The analysis was done with PhotoShop 7.0 software. (G) Cartoon showing in vitro and
in vivo Co-TIC/stromal cell coculture models.
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Co-TICs have been found to express a variety of surface markers,
including CD133 [3]. CD133 is a transmembrane glycoprotein mol-
ecule with a molecular weight of 120 kDa on chromosome 4p15.32.
CD133+ cancer cells were shown to have the ability to self-renew,
retain tumorigenicity, and regenerate a tumor after treatment [18]. Li
et al. [28] have shown that, in stage IIIB colon cancer, recurrence
correlated with the percentage of CD133+ cells present in the original
tumor. Whereas CD133+ cells have been shown to meet all the char-
acteristics of TIC, its specificity as a true Co-TICmarker has been ques-
tioned [29]. Other markers such as aldehyde dehydrogenase 1,
epithelial specific antigen (Ep-CAM or CD326), CD44, and CD166
have also been used to identify Co-TICs. More recently, Wnt signaling
activity combined with cellular interaction with the microenvironment
has been deemed as a marker for Co-TIC [30]. In our experiments, we
Figure 5. (continued).
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primarily used CD133 as Co-TIC marker to enrich TICs from HT-29
cells and CRC patient cells. These cells were able to initiate tumors
in immunodeficient mice in the presence of HK cells and HK cell–
conditioned media. Although the ideal Co-TIC marker is yet to be
determined, we were able to show that a small proportion of Co-TICs
display CD133+CXCR4+. Cell sorting with an additional marker
increased the target cancer cell’s tumor–initiating ability by 100-fold
(Table 1), agreeing with the observations of Dalerba et al. [31]. In addition,
double-positive cells were enriched in chemotherapy-resistant cell pop-
ulation. Our data indicate that CD133 and CXCR4 may be better
markers for drug-resistant Co-TICs.
The 5-year survival rate of the American Joint Committee on
Cancer stage I CRC is 90% and decreases to 75% and 50% for
stage II and III patients, respectively. Tumor invasion and regional
LN metastases are important factors for determining CRC prognosis.
Prognostic markers are urgently needed for CRC, especially for stage II
patients. Recently, several studies have focused on such prognostic
markers. Saiki et al. [32], using reverse transcription–polymerase chain
reaction analysis, revealed that the expression of stem cell–related genes,
including LIN28 and SOX2, correlated with LN metastasis. Although
the CRC tumor tissues that were examined had been collected by laser
microdissection, these results may indicate that the Co-TIC population
is increased in metastatic sites. When putative TIC markers were tested
in CRC tumor buds, ABCG5 and EpCAM were significantly asso-
ciated with a poorer prognosis [33]. However, most published studies
have been conducted with bulk tumor samples without differentiating
the response between Co-TIC and non-TIC. Because Co-TICs are
such a small population, precise analysis of prognostic markers within
Co-TICs may yield more accurate prognostic significance.
SDF-1α is one of many soluble microenvironmental factors pro-
duced by FDCs in a paracrine fashion [34]. The SDF-1α/CXCR4 axis
is associated with in vitro CRC migration, lymphatic and distant dis-
semination, disease recurrence, and decreased survival rate [9,11,35]. In
our experiments, drug-resistant CRC cells showed an increased expres-
sion of CD133 and CXCR4. Our observation is in agreement with
those of Dessein et al. [36]; they recently demonstrated that induction
of CXCR4 acts as a major mechanism underlying invasion in drug-
resistant colon carcinoma HT-29 cells. This phenomenon is not
limited to CRC because CD133+CXCR4+ migrating TICs are shown
to play a crucial role in tumor initiation, growth, and metastasis in
human pancreatic, prostate, and breast cancers [12,37].
Although it has been widely accepted that only rare TIC populations
within human leukemia can seed leukemia in mice [38], this assertion
about TICs is still controversial for solid tumors. In solid tumors, most
in vivo studies generate human tumor xenografts from immunodeficient
mice, a foreign microenvironment for human cancers. It was shown that
as few as 100 purified TICs could initiate tumors in immunodeficient
mice [39]. It is unclear whether this phenomenon represents a selection
of surviving cells in a foreign environment or whether it is due to the
presence of TIC because, in syngeneic animals, a dominant cell popula-
tion rather than rare TICs seems to sustain many tumors. In our in vivo
model, human stromal HK cells were coinoculated with CRC patient
cells, recreating a humanized microenvironment similar to a LN, a com-
mon destination for CRCmetastasis. A similar method was also reported
in breast cancer studies [40], where an orthotopic xenograft model was
established in which both the stromal and epithelial components of the
reconstructed mammary gland were of human origin, providing the
proper environment for the development of humanmammary epithelium.
Our data show that coinjection of HK cells is essential for CD133+
Co-TIC to form tumor in immunodeficient mice and that HK cells
selectively support Co-TICs’ survival from chemotherapeutic drugs.
Indeed, cells positive for ABCG2, a multidrug pump, were also pos-
itive for CD133 and CXCR4 (Figure W2B).
The existence of Co-TICs may be the underlying reason for che-
motherapeutic drug resistance. Indeed, when treated with standard
chemotherapeutic agents for CRC, both in vitro and in vivo chemo-
therapeutic treatment-resistant HT-29 cells were enriched with
CD133+CXCR4+ Co-TIC. Our data are consistent with the findings
by Dylla et al. [41] and Todaro et al. [42] in that Co-TICs were
enriched in colon tumors after treatment with chemotherapeutic
drugs. These cells remained capable of rapidly regenerating pheno-
typical similar tumors. In our models, both HT-29 and CRC patient
cells, Co-TICs were enriched by chemotherapy in the presence of HK
cells. This enrichment suggests that targeting Co-TICs alone may not
suffice to minimize recurrence and that future treatments must target
LN microenvironmental support as well.
The intriguing result from our stromal cell or stromal cell–
conditioned media/colon cancer cell coculture and coimplantation
studies is that LN stomal cells provide SDF-1α to assist CXCR4-
expressing CD133+ Co-TICs in xenoplant tumor formation of both
CRC patient tumor cells and HT-29 cells. It is likely that drug-
resistant CD133+CXCR4+ Co-TICs are regulated in a paracrine man-
ner by SDF-1α derived fromHK cells (Figure 5G). AMD3100 partially
blocked the stromal/colon cancer cell tumor formation, indicating that
SDF-1α is crucial to CD133+CXCR4+ Co-TICs. This finding is in
agreement with a recent report that Co-TIC marker Wnt-signaling ac-
tivity was regulated by the microenvironmental myofibroblast-secreted
factors [30], implicating the microenvironment as a dominant factor in
Co-TICs. FDCs may promote Co-TIC tumor growth in two ways: 1)
by supporting Co-TIC survival and activation for tumor initiation by
providing soluble factors, such as SDF-1α; and 2) by enhancing the
host’s response to increase tumor angiogenesis.
In addition to providing evidence in support of the TIC hypothe-
sis, this study provides multiple lines of evidence that Co-TICs serve a
crucial role in CRC tumor growth and chemotherapy drug resistance.
Even more importantly, it determines the influence of LN stromal
cells on Co-TICs’ survival, chemoresistance, and stimulation. We
have identified a major Co-TIC/LN microenvironment-specific
mechanism of chemotherapeutic resistance and established both
in vitro and in vivo platforms for testing novel agents against both
Co-TIC and LN microenvironmental factors. Our data indicate that
SDF-1α from LN stromal cells and its receptor CXCR4 are possible
targets for clinical therapy (Figure 5G ). Closer scrutiny of TIC and
its supporting LN microenvironmental factors will lead to a better
understanding of mechanisms of extranodal CRC recurrence and
metastasis and, ultimately, to novel targeted therapies.
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Figure W1. GFP signal from viable GFP–HT-29 cells correlates with the WST-1 assay. GFP-tagged HT-29 cells (0, 375, 750, 1500, 3000,
6000, 12,000, and 24,000 cells/well in 96-well plates) were cultured in McCoy medium for 2 hours. GFP signals were measured by IVIS
Lumina Imaging System (A) and WST-1 absorption OD650-450nm (B) values were analyzed for correlation using Prism Version 4.03 (C).
Inserts in A show microscopic images of contrast and GFP of HT-29 cells in representative wells using a Leica Fluorescent Microscope
with Spot software (Diagnostic Instruments, Sterling Heights, MI). Images show GFP+ HT-29 cells.
Figure W2. Detecting Co-TICs in CRC. (A) Frozen tumor tissue sections from CRC patients 25 and 27 were triple stained for CD326,
CD133, and CXCR4. DAPI was used as a nuclear counterstain. Original magnification, ×400. (B) HT-29 and HCA-7 cells were triple
stained with ABCG2-FITC, CXCR4-PE, and CD133-APC for flow cytometry using FACSCalibur with CellQuest software and were analyzed
using FlowJo software.
Figure W3. Purification of CD133+ Co-TIC. (A) HT-29 cells (top) and CRC cells from patient 7 (bottom) were magnetically labeled and
separated by double passage using a CD133 Cell Isolation Kit (Miltenyi Biotec). Numbers indicate mean fluorescence intensity of CD133
staining. (B) Purified CD133+ cells from A were confirmed by FACS analysis. Numbers indicate CD133+ cell percentages.
Figure W4. HK cells support chemotherapeutic drug–resistant colon cancer cells. Cancer cells were cultured with or without HK cells.
Chemotherapeutic drug treatments were same as Figure 4A. Images were taken using Leica Fluorescent Microscope with Spot soft-
ware. Fluorescent microscopy images showing GFP+ cancer cell densities.
Figure W5. HK cell phenotype. (A) HK cells were stained with PE-conjugated anti-SMA Ab or isotype control. Image was taken using
deconvoluting microscope. Original magnification, ×400. (B) HK cells were stained with indicated Abs for FACS analysis. Numbers
indicate positive cell percentages.
Table W1. Extreme Limiting Dilution Analysis of Sphere-Forming Frequency of HT-29 and HCA-7 Cells.
No. Cells/Well HT-29 HCA-7
No. Wells Plated No. Wells Showing Spheres No. Wells Plated No. Wells Showing Spheres
SCM SCM + 50% HK CM SCM SCM + 50% HK CM
10,000 24 24 24 18 18 18
1000 24 24 24 18 18 18
100 24 3 19 18 5 18
10 24 2 14 18 3 9
1 24 0 9 18 0 9
Sphere-forming frequency (95% CI) 1/308 (1/194-1/490) 1/29 (1/18-1/45) 1/200 (1/111-1/361) 1/8 (1/5-1/14)
P 1.86e−14 1.11e−16
CI indicates confidence interval.
